Aequus Pharmaceuticals Inc.

AQS

CA0076361033

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 15:30:50 2024-05-16 EDT			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		+25.00%	0.00%

05-10	Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-30	Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors

April 05, 2023 at 08:30 am

Aequus Pharmaceuticals Inc. announced the resignation of Stuart Fowler from the Board of Directors. Stu has been a leader in the Canadian Eye Care space for years.

Latest news about Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Aequus Says Zimed PF Now Available in Canada	23-08-24	MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada	23-08-24	CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch	23-08-22	MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada	23-08-18	MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada	23-08-18	CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free	23-07-07	MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf	23-07-05	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors	23-04-05	CI
Aequus Announces Health Canada Notice of Compliance for Zimed® Preservative Free (Bimatoprost 0.03%)	22-12-20	CI
Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF	22-11-29	MT
Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)	22-11-29	CI
Aequus Pharmaceuticals Inc. Agrees to End Its Promotional Service Agreement with Sandoz Canada Inc	22-11-29	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Aequus Pharmaceuticals Chairman and CEO Doug Janzen Increases Ownership Interest	22-07-25	MT
Aequus Signs Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products	22-07-07	MT
Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products	22-07-06	CI
Aequus Pharmaceuticals Reports FY 2021, Q1 2022, Financial Results	22-07-04	MT

Chart Aequus Pharmaceuticals Inc.

Duration

Period

More charts

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AEQUUS PHARMACEUTICALS INC.	0.00%	2.93M
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals